PsART-ID起始队列:银屑病关节炎患者的临床特征、治疗选择与结局
PsArt-ID多中心注册研究纳入诊断≤6个月的早期PsA患者388例为起始队列,并与病程5-10年(328例)及≥10年(326例)的已确诊队列比较。结果显示起始队列与已确诊队列在多关节炎和单-寡关节炎表现上相当,但≥10年队列的中轴受累、指炎和甲受累率更高,附着点炎和畸形率在起始队列较低;甲氨蝶呤是所有队列最常用治疗,早期患者16个月后10.7%使用抗TNF药物。
要点
- 早期PsA与已确诊队列疾病模式无显著差异,但中轴受累在≥10年队列更高。
- 指炎和甲受累率在诊断10年后显著增加,附着点炎和畸形随时间呈上升趋势。
- 甲氨蝶呤是所有队列最常用治疗,早期患者16个月后10.7%使用抗TNF药物。
核心结论
- 真实世界中PsA患者除中轴受累外疾病模式率无显著差异,指炎和甲受累率在诊断10年后显著增加,附着点炎和畸形随时间呈上升趋势。
研究设计与样本
- PsArt-ID为多中心注册研究,起始队列为诊断PsA≤6个月的患者388例,已确诊队列分为诊断后5-10年328例和≥10年326例。
主要发现
- 起始队列平均年龄44.7岁(s.d. 13.3),男性167/388例(43.0%)。
- ≥10年队列中轴受累率为34.8%,起始队列为27.7%。
- 指炎和甲受累率在≥10年队列更高(P=0.004,P=0.001)。
- 起始队列附着点炎和畸形率较低,起始组13%患者存在畸形。
- 甲氨蝶呤是所有队列最常用治疗,早期PsA患者16个月后10.7%使用抗TNF药物。
临床怎么用
- 早期PsA应关注中轴受累评估,随病程延长需监测指炎、甲受累、附着点炎及畸形进展。
- 甲氨蝶呤是各阶段最常用治疗,早期患者16个月后约十分之一使用抗TNF药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Our aim is to understand clinical characteristics, real-life treatment strategies, outcomes of early PsA patients and determine the differences between the inception and established PsA cohorts. METHODS: PsArt-ID (Psoriatic Arthritis- International Database) is a multicentre registry. From that registry, patients with a diagnosis of PsA up to 6 months were classified as the inception cohort (n==388). Two periods were identified for the established cohort: Patients with PsA diagnosis within 5-10 years (n = 328), ≥10 years (n = 326). Demographic, clinical characteristics, treatment strategies, outcomes were determined for the inception cohort and compared with the established cohorts. RESULTS: The mean (s.d.) age of the inception cohort was 44.7 (13.3) and 167/388 (43.0%) of the patients were male. Polyarticular and mono-oligoarticular presentations were comparable in the inception and established cohorts. Axial involvement rate was higher in the cohort of patients with PsA ≥10 years compared with the inception cohort (34.8% vs 27.7%). As well as dactylitis and nail involvement (P = 0.004, P = 0.001 respectively). Both enthesitis, deformity rates were lower in the inception cohort. Overall, 13% of patients in the inception group had a deformity. MTX was the most commonly prescribed treatment for all cohorts with 10.7% of the early PsA patients were given anti-TNF agents after 16 months. CONCLUSION: The real-life experience in PsA patients showed no significant differences in the disease pattern rates except for the axial involvement. The dactylitis, nail involvement rates had increased significantly after 10 years from the diagnosis and the enthesitis, deformity had an increasing trend over time.
引用
- Ayan G, Aydin SZ, Kimyon G, et al. PsART-ID inception cohort: clinical characteristics, treatment choices and outcomes of patients with psoriatic arthritis. Rheumatology (Oxford). 2021. PMID: 33097960. doi:10.1093/rheumatology/keaa663
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。